Visugromab (CTL-002)
Metastatic Non-squamous Non-Small Cell Lung Cancer (2nd line)
Key Facts
About CatalYm
CatalYm is a clinical-stage biotech focused on overcoming cancer therapy resistance by neutralizing GDF-15 (Growth Differentiation Factor-15), a key immunosuppressant hijacked by tumors. The company's lead asset, visugromab, has demonstrated durable objective responses in Phase 1/2a trials in checkpoint inhibitor-refractory metastatic solid tumors. With an experienced leadership team, CatalYm is now expanding its clinical program into Phase 2b studies in non-small cell lung cancer (NSCLC) and other indications, positioning visugromab as a potential backbone combination therapy in immuno-oncology.
View full company profileAbout CatalYm
CatalYm is a clinical-stage biotech focused on overcoming cancer therapy resistance by neutralizing GDF-15 (Growth Differentiation Factor-15), a key immunosuppressant hijacked by tumors. The company's lead asset, visugromab, has demonstrated durable objective responses in Phase 1/2a trials in checkpoint inhibitor-refractory metastatic solid tumors. With an experienced leadership team, CatalYm is now expanding its clinical program into Phase 2b studies in non-small cell lung cancer (NSCLC) and other indications, positioning visugromab as a potential backbone combination therapy in immuno-oncology.
View full company profileAbout CatalYm
CatalYm is a clinical-stage biotech focused on overcoming cancer therapy resistance by neutralizing GDF-15 (Growth Differentiation Factor-15), a key immunosuppressant hijacked by tumors. The company's lead asset, visugromab, has demonstrated durable objective responses in Phase 1/2a trials in checkpoint inhibitor-refractory metastatic solid tumors. With an experienced leadership team, CatalYm is now expanding its clinical program into Phase 2b studies in non-small cell lung cancer (NSCLC) and other indications, positioning visugromab as a potential backbone combination therapy in immuno-oncology.
View full company profile